Error message

User warning: The following theme is missing from the file system: WORKING_COPY. For information about how to fix this, see the documentation page. in _drupal_trigger_error_with_delayed_logging() (line 1143 of /home/insysbi8/insysbio.com/docs/includes/bootstrap.inc).

InSysBio Announces Continuation of Collaboration with MedImmune for Quantitative Systems Pharmacology Modeling in Systemic Lupus Erythematosus

 

October 1, 2018

InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP), modeling and simulation for drug development, announced today an extension of a collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for QSP modeling in systemic lupus erythematosus (SLE). The goal is to support the clinical development of anifrolumab, an investigational monoclonal antibody against the type I interferon receptor, by modeling the contributions of key cell types involved in the pathophysiology of lupus that are associated with the type I interferon dysregulation commonly seen with the disease.

“InSysBio’s QSP modeling approach helps us not only to identify predictive biomarkers and means of stratifying patients but also to understand how these biomarkers are related to anifrolmab’s mechanism of action,” said Wendy White, Scientific Director, MedImmune.

“This project is another example of the usefulness of QSP modeling not only in early stages of drug development but also in late stages,” said Oleg Demin Jr, Head of Business Development, InSysBio.

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit http://insysbio.com.

Tags: 
PRESS-RELEASE